BAJAJ BROKING

Notification close image
No new Notification messages
card image
Euro Pratik Sales Ltd IPO
Apply for the Euro Pratik Sales Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

538965

CONCORD

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Concord Drugs Limited Share Price Update

As of the latest trading session, Concord Drugs Limited share price is currently at ₹ 67.18, which is down by ₹ -1.37 from its previous closing. Today, the stock has fluctuated between ₹ 67.18 and ₹ 67.18. Over the past year, Concord Drugs Limited has achieved a return of 80.91 %. In the last month alone, the return has been 34.41 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Concord Drugs Limited fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    67.20

  • P/E Ratio (TTM)

    171.38

  • Beta

    0.48

  • Book Value / share

    34.11

  • Return on equity

    1.28%

  • EPS (TTM)

    0.40

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    0.11

info icon alternate text

Concord Drugs Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 13.38
Operating Expense 13.23
Net Profit 0.11
Net Profit Margin (%) 0.82
Earnings Per Share (EPS) 0.11
EBITDA 0.94
Effective Tax Rate (%) 26.66
Particulars MAR 2025 (Values in Cr)
Revenue 7.96
Operating Expense 7.94
Net Profit 0.01
Net Profit Margin (%) 0.12
Earnings Per Share (EPS) 0.01
EBITDA 0.92
Effective Tax Rate (%) 50.00
Particulars DEC 2024 (Values in Cr)
Revenue 10.77
Operating Expense 10.26
Net Profit 0.22
Net Profit Margin (%) 2.04
Earnings Per Share (EPS) 0.22
EBITDA 1.31
Effective Tax Rate (%) 57.69
Particulars SEP 2024 (Values in Cr)
Revenue 11.84
Operating Expense 11.78
Net Profit 0.05
Net Profit Margin (%) 0.42
Earnings Per Share (EPS) 0.05
EBITDA 0.80
Effective Tax Rate (%) 28.57
Particulars JUN 2024 (Values in Cr)
Revenue 6.35
Operating Expense 6.33
Net Profit 0.01
Net Profit Margin (%) 0.15
Earnings Per Share (EPS) 0.01
EBITDA 0.74
Effective Tax Rate (%) 33.33
Particulars MAR 2025 (Values in Cr)
Revenue 36.93
Operating Expense 36.31
Net Profit 0.30
Net Profit Margin (%) 0.81
Earnings Per Share (EPS) 0.30
EBITDA 3.78
Effective Tax Rate (%) 54.68
Particulars MAR 2024 (Values in Cr)
Revenue 43.26
Operating Expense 42.71
Net Profit 0.42
Net Profit Margin (%) 0.97
Earnings Per Share (EPS) 0.42
EBITDA 3.69
Effective Tax Rate (%) 25.00
Particulars MAR 2023 (Values in Cr)
Revenue 51.31
Operating Expense 50.19
Net Profit 0.89
Net Profit Margin (%) 1.73
Earnings Per Share (EPS) 0.96
EBITDA 4.35
Effective Tax Rate (%) 20.35
Particulars MAR 2022 (Values in Cr)
Revenue 58.96
Operating Expense 56.81
Net Profit 1.59
Net Profit Margin (%) 2.69
Earnings Per Share (EPS) 1.82
EBITDA 5.68
Effective Tax Rate (%) 28.88
Particulars MAR 2021 (Values in Cr)
Revenue 51.36
Operating Expense 50.92
Net Profit 3.28
Net Profit Margin (%) 6.38
Earnings Per Share (EPS) 3.75
EBITDA 7.08
Effective Tax Rate (%) 23.54
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.82
ROE % 1.43
ROCE % 4.76
Total Debt to Total Equity 0.53
EBITDA Margin 9.02
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 3.30
ROCE % 6.04
Total Debt to Total Equity 0.56
EBITDA Margin 8.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.61
ROCE % 8.36
Total Debt to Total Equity 0.58
EBITDA Margin 9.65
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.82
ROE % 1.28
ROCE % 4.25
Total Debt to Total Equity 0.47
EBITDA Margin 8.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 2.96
ROCE % 5.67
Total Debt to Total Equity 0.53
EBITDA Margin 8.48
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.77
ROCE % 8.80
Total Debt to Total Equity 0.53
EBITDA Margin 9.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.61
ROE % 1.59
ROCE % 5.01
Total Debt to Total Equity 0.45
EBITDA Margin 6.46
Particulars MAR 2020 (Values in Cr)
Book Value / Share 26.86
ROE % 1.42
ROCE % 5.61
Total Debt to Total Equity 0.42
EBITDA Margin 6.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.17
Total Assets 58.80
Total Liabilities 58.80
Total Equity 33.81
Share Outstanding 10000000
Price to Book Ratio 1.04
Return on Assets (%) 0.80
Return on Capital (%) 0.94
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 58.23
Total Liabilities 58.23
Total Equity 31.70
Share Outstanding 9315470
Price to Book Ratio 0.82
Return on Assets (%) 1.69
Return on Capital (%) 2.06
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 8743750
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 56.29
Total Liabilities 56.29
Total Equity 33.81
Share Outstanding 10000000
Price to Book Ratio 1.04
Return on Assets (%) 0.74
Return on Capital (%) 0.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 56.63
Total Liabilities 56.63
Total Equity 31.70
Share Outstanding 9315470
Price to Book Ratio 0.82
Return on Assets (%) 1.57
Return on Capital (%) 1.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 8743750
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 49.88
Total Liabilities 49.88
Total Equity 26.76
Share Outstanding 8743750
Price to Book Ratio 0.95
Return on Assets (%) 6.57
Return on Capital (%) 8.26
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 58.01
Total Liabilities 58.01
Total Equity 23.48
Share Outstanding 8743750
Price to Book Ratio 0.49
Return on Assets (%) 0.56
Return on Capital (%) 0.99
Particulars MAR 2024 (Values in Cr)
Net Income 0.62
Cash from Operations 1.01
Cash from Investing -1.00
Cash from Financing 0.28
Net change in Cash 0.06
Free Cash Flow 2.03
Particulars MAR 2023 (Values in Cr)
Net Income 1.24
Cash from Operations 2.04
Cash from Investing -2.26
Cash from Financing 0.62
Net change in Cash 0.02
Free Cash Flow 2.89
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2024 (Values in Cr)
Net Income 0.55
Cash from Operations 2.16
Cash from Investing -1.20
Cash from Financing -0.68
Net change in Cash 0.06
Free Cash Flow 3.18
Particulars MAR 2023 (Values in Cr)
Net Income 1.12
Cash from Operations 2.59
Cash from Investing -2.26
Cash from Financing 0.05
Net change in Cash 0.03
Free Cash Flow 3.44
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2021 (Values in Cr)
Net Income 4.29
Cash from Operations 2.08
Cash from Investing -3.66
Cash from Financing 2.07
Net change in Cash 0.02
Free Cash Flow 5.76
Particulars MAR 2020 (Values in Cr)
Net Income 0.45
Cash from Operations 2.60
Cash from Investing -0.84
Cash from Financing -1.79
Net change in Cash -0.14
Free Cash Flow 3.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 30.85 12.59 1.68 236.41 30.00 / 68.00
BLISS GVS PHARMA LTD 152.60 15.11 1.53 1611.02 105.05 / 190.65
CIPLA LTD 1559.25 23.36 4.03 125949.05 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 351.10 9.89 2.84 1033.32 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 30.85 16.77 4.87 236.41 30.00 / 68.00
AMRUTAJAN HEALTH LTD 767.00 40.67 6.78 2217.45 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9139.40 108.04 29.65 22848.50 6222.35 / 10653.05
BLISS GVS PHARMA LTD 152.60 22.81 1.52 1611.02 105.05 / 190.65

Concord Drugs Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
67.18 -1.99 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 68.70
  • 26 Days 62.50
  • 10 Days 67.20
  • 50 Days 57.60
  • 12 Days 66.50
  • 100 Days 50.60
  • 20 Days 64.00
  • 200 Days 44.60
69.01 PIVOT

First Support

68.09

First Resistance

69.46

Second Support

67.64

Second Resistance

70.38

Third Support

66.72

Third Resistance

70.83

RSI

69.89

ADX

42.98

MACD

4.01

Williams % R

-16.52

Commodity Channel Index (CCI)

80.10

Date

2025-09-17

Week

7383.00

Same Day

3440.00

Month

11130.00

1 Year

0.48

3 Year

0.49

Over 1 Month

34.41%

down

Over 1 Year

80.91%

down

Over 3 Months

128.50%

down

Over 3 Years

27.59%

down

Over 6 Months

101.38%

down

Over 5 Years

31.10%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Concord Drugs Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
45.6%
Promoter Holdings
54.39%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nagi Reddy Seelam 2860536.0 (28.61%) Shareholding of Promoter and Promoter Group
Manoj Kumar Reddy Seelam 1628125.0 (16.28%) Shareholding of Promoter and Promoter Group
Seelam Koni Reddy 950543.0 (9.51%) Shareholding of Promoter and Promoter Group
Pradeep Kumar Jain 272084.0 (2.72%) Public Shareholding
Rajender Kumar Agarwal 159866.0 (1.6%) Public Shareholding
S N Thulasi Devi 121200.0 (1.21%) Public Shareholding
K Ramesh Reddy 104600.0 (1.05%) Public Shareholding
Sannuthi Lokesh 100000.0 (1.0%) Public Shareholding
Rakesh K 100000.0 (1.0%) Public Shareholding
Ekta Vijaywargi 99999.0 (1.0%) Public Shareholding
Mohan Thodupunuri 100006.0 (1.0%) Public Shareholding

News

Left Arrow
Right Arrow

Concord Drugs Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Concord Drugs Limited Share Price

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets.

The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality.

The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.

Parent organization Indian Private
NSE symbol [-]
Founded 1995
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Concord Drugs Ltd?

Answer Field

Concord Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 67.18 as on Sep 18 2025 03:15 PM.

What is the Market Cap of Concord Drugs Ltd Share?

Answer Field

The market cap of Concord Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 67.20 as on Sep 18 2025 03:15 PM.

What is the 52 Week High and Low of Concord Drugs Ltd?

Answer Field

The 52 Week High and Low of Concord Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 71.00 and ₹ 26.10.

What is 1 year return for Concord Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 80.91%.

What is the P/E Ratio of Concord Drugs Ltd Share?

Answer Field

As on Sep 18 2025 03:15 PM the price-to-earnings (PE) ratio for Concord Drugs Ltd share is 171.38.

What is the PB ratio of Concord Drugs Ltd Share?

Answer Field

As on Sep 18 2025 03:15 PM, the price-to-book (PB) ratio for Concord Drugs Ltd share is 34.11.

How to Buy Concord Drugs Ltd Share?

Answer Field

You can trade in Concord Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Concord Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Concord Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Concord Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91